Skip to main content
XNCR
NASDAQ Life Sciences

Xencor Swings to $39.4M Profit as Royalties and Milestones Lift Revenue 5x

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$34.975
Mkt Cap
$2.601B
52W Low
$10.375
52W High
$35.05
52W Position info
237% above low
Off High info
at 52W high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

XNCR has more than doubled off its 52-week low of $10.375.

Summary

Xencor flipped to a $39.4 million profit, or $0.50 per diluted share, in Q3 2026 from a $6.0 million loss a year earlier, as revenue jumped to $116.5 million from $21.0 million on Alexion and Incyte royalties plus an Astellas milestone. Cash and marketable securities stood at $555.7 million at September 30, and management guided to $480-500 million at year-end with funding into 2029 — no financing need in sight. The quarter also carried partnership momentum: Astellas dosed the first patient in the ASP2138 Phase 3, triggering a $25.0 million payment, and Zenas' partner Bristol Myers Squibb filed a Japan MAA for obexelimab, adding $2.5 million. R&D spending rose to $84.3 million from $54.4 million as the XmAb819 program scales toward a planned Phase 3 in advanced ccRCC, following the October ESMO data and 400 mcg/kg dose selection. Near-term readout: early plamotamab dose-escalation data in rheumatoid arthritis at ACR on November 9.

At the time of this announcement, XNCR was trading at $34.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $10.38 to $35.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

XNCR - Latest Insights

XNCR
Nov 04, 2026, 4:02 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $33.09 info
Change: -$2.91 (-8%) info
Market Cap: $2.552B info
XNCR
Oct 26, 2026, 1:00 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $30.18
Real-time Price: $33.09 info
Change: +$2.92 (+10%) info
Market Cap: $2.552B info
XNCR
Oct 26, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.02
Real-time Price: $33.09 info
Change: -$0.9335 (-3%) info
Market Cap: $2.552B info
XNCR
Oct 25, 2026, 4:35 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $25.55
Real-time Price: $33.09 info
Change: +$7.54 (+30%) info
Market Cap: $2.552B info
XNCR
Aug 05, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.84
Real-time Price: $33.09 info
Change: +$13.25 (+67%) info
Market Cap: $2.552B info